$2.45T
Total marketcap
$76.09B
Total volume
BTC 50.61%     ETH 14.85%
Dominance

Neurogenesis NEUN Stock

0.0001 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
Other OTC
Market Cap
8.23K USD
LOW - HIGH [24H]
0.0001 - 0.0001 USD
VOLUME [24H]
10K USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

Neurogenesis Price Chart

Neurogenesis NEUN Financial and Trading Overview

Neurogenesis stock price 0.0001 USD
Previous Close 0.0001 USD
Open 0.0001 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 0.0001 - 0.0001 USD
52 Week Range 0.0001 - 0.0075 USD
Volume 5K USD
Avg. Volume 163 USD
Market Cap 8.23K USD
Beta (5Y Monthly) -18.130985
PE Ratio (TTM) Infinity
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

NEUN Valuation Measures

Enterprise Value 2.03K USD
Trailing P/E Infinity
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.007691725
Price/Book (mrq) N/A
Enterprise Value/Revenue 0.002
Enterprise Value/EBITDA N/A

Trading Information

Neurogenesis Stock Price History

Beta (5Y Monthly) -18.130985
52-Week Change -98.66%
S&P500 52-Week Change 20.43%
52 Week High 0.0075 USD
52 Week Low 0.0001 USD
50-Day Moving Average 0.0001 USD
200-Day Moving Average 0.004392 USD

NEUN Share Statistics

Avg. Volume (3 month) 163 USD
Avg. Daily Volume (10-Days) 0 USD
Shares Outstanding 82.26M
Float N/A
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2006
Most Recent Quarter (mrq) June 30, 2012
Next Fiscal Year End December 31, 2007

Profitability

Profit Margin -0.89%
Operating Margin (ttm) -0.088%
Gross Margin 79.62%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 1.07M USD
Revenue Per Share (ttm) 0.02 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 1.06M USD
EBITDA N/A
Net Income Avi to Common (ttm) -9602 USD
Diluted EPS (ttm) 0
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) N/A
Total Cash Per Share (mrq) N/A
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 4.449
Book Value Per Share (mrq) -0.004

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of Neurogenesis

Country United States
State TX
City League City
Address 1241 Butler Road
ZIP 77573
Phone 281 557 7877
Website https://www.neurogenesis.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.

Q&A For Neurogenesis Stock

What is a current NEUN stock price?

Neurogenesis NEUN stock price today per share is 0.0001 USD.

How to purchase Neurogenesis stock?

You can buy NEUN shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Neurogenesis?

The stock symbol or ticker of Neurogenesis is NEUN.

Which industry does the Neurogenesis company belong to?

The Neurogenesis industry is Drug Manufacturers-Specialty & Generic.

How many shares does Neurogenesis have in circulation?

The max supply of Neurogenesis shares is 82.26M.

What is Neurogenesis Price to Earnings Ratio (PE Ratio)?

Neurogenesis PE Ratio is now.

What was Neurogenesis earnings per share over the trailing 12 months (TTM)?

Neurogenesis EPS is 0 USD over the trailing 12 months.

Which sector does the Neurogenesis company belong to?

The Neurogenesis sector is Healthcare.